Drug intelligence / Profile preview

PB1103

Development stage: Preclinical
Lead developer: PEG Biosciences
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular

Overview

PB1103 is an investigational synergy interferon-alfa biologic developed by PEG Biosciences using its proprietary BioSynersys™ platform. This platform creates 'Synergy PEG-enhanced biologics' designed to improve the pharmacological properties of the protein. PB1103 targets the interferon-alfa pathway and is intended for the treatment of various oncology and viral indications, including kidney cancer, melanoma, Kaposi sarcoma, hairy cell leukemia (HCL), chronic myeloid leukemia (CML), and hepatitis B and C. Compared to standard pegylated interferon-alfa, PB1103 is designed to provide increased, sustained, and prolonged biological activity in blood plasma, potentially offering superior efficacy in treating hematologic cancers and viral diseases.

Other names: synergy interferon-alfa

Beyond the preview

Go deeper on PB1103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB1103.